Cellusion and Toyo Seikan Group Holdings enter Capital and Business Alliance of CLS001 for Corneal Endothelial Cell Regenerative Therapy

Cellusion established the Board of Corporate Auditors

Announcement of Changes to Officer Personnel

Cellusion’s Series B fundraising was introduced in BioWorld

Cellusion obtained JHVS Venture Award 2021

Cellusion Raises 1.1B JPY to Advance Japan and Global Clinical Trials of CLS001 for Corneal Endothelial Cell Regenerative Therapy

Cellusion and Toho Holdings enter Capital and Business Alliance of CLS001 for Corneal Endothelial Cell Regenerative Therapy

Cellusion welcomes Dr. Naonori Kurokawa and Dr. Hiroaki Kobayashi to the Management Team

Cellusion obtained 1st prize of JHVS2021 Global Pitch

Cellusion participated the mini seminar in ISSCR & JSRM 2021 Tokyo International Symposium “Stem Cells: From Basic Science to Clinical Translation”